We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Arrowhead

News List

Arrowhead Pharma purchases land ahead of new manufacturing facility buildout CPhIonline
December 22, 2021
New campus will support the company as it approaches potential commercialisation of its rapidly progressing clinical candidates.
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress firstwordpharma
June 28, 2021
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented additional positive interim 48-week liver biopsy results from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT
Arrowhead and Horizon enter up to $700m deal to develop RNAi drug pharmaceutical-technology
June 23, 2021
Arrowhead Pharmaceuticals and Horizon Therapeutics have entered a global partnership and licence agreement to develop the former’s ribonucleic acid interference (RNAi) therapeutic, ARO-XDH.
Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B biospace
March 28, 2018
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2 clinical study of ARO-HBV